Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma
BackgroundDiffuse large B-cell lymphoma (DLBCL) is a heterogeneous group with varied pathophysiological, genetic, and clinical features, accounting for approximately one-third of all lymphoma cases worldwide. Notwithstanding that unprecedented scientific progress has been achieved over the years, th...
Main Authors: | Jiaqin Yan, Wei Yuan, Junhui Zhang, Ling Li, Lei Zhang, Xudong Zhang, Mingzhi Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-04-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.846357/full |
Similar Items
-
Development and validation of nomograms by radiomic features on ultrasound imaging for predicting overall survival in patients with primary nodal diffuse large B-cell lymphoma
by: Hongyan Deng, et al.
Published: (2022-12-01) -
Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma
by: Xiaoshuang Kong, et al.
Published: (2023-04-01) -
Construction and Validation of a Novel Nomogram for Predicting the Recurrence of Diffuse Large B Cell Lymphoma Treated with R-CHOP
by: Gong Y, et al.
Published: (2023-04-01) -
Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma
by: Chengliang Yin, et al.
Published: (2020-08-01) -
A novel lipid metabolism-based risk model associated with immunosuppressive mechanisms in diffuse large B-cell lymphoma
by: Zhaoli Zhang, et al.
Published: (2024-01-01)